

1 **Original Article**

2

3 **Lack of latent tuberculosis screening in HIV patients and delay in Anti-**
4 **Retroviral Therapy initiation in HIV-TB co-infection: A 11-year study in an**
5 **intermediate TB-burden country**

6 Vannesa Yue May Teng¹, Yan Ting Chua¹, Eunice En Ni Lai¹, Shilpa Mukherjee¹,
7 Jessica Michaels¹, Chen Seong Wong^{2,3}, Yee Sin Leo^{2,3,4}, Barnaby Young^{2,3,4},
8 Sophia Archuleta^{1,5}, Catherine W.M. Ong^{1,5,6}

9

10 **Affiliations**

11 ¹Department of Medicine, National University Hospital, National University Health
12 System Singapore;

13 ²National Centre for Infectious Disease, Singapore

14 ³Department of Infectious Disease, Tan Tock Seng Hospital, Singapore

15 ⁴Lee Kong Chian school of Medicine, Nanyang Technological University Singapore,
16 Singapore

17 ⁵Department of Medicine, Yong Loo Lin School of Medicine, National University of
18 Singapore

19 ⁶Institute for Health Innovation & Technology, National University of Singapore

20

21 Corresponding Author:

22 Vannesa Teng Yue May

23 10th floor Tower Block, 1E Kent Ridge Road, Singapore 119228

24 vannesa_teng@nuhs.edu.sg

25 Telephone number: +65 98164277

26

27 Co-Corresponding Author

28 Catherine W.M. Ong

29 10th floor Tower Block, 1E Kent Ridge Road, Singapore 119228

30 Email: catherine_wm_ong@nuhs.edu.sg

31 Telephone number: +65 6772 7854

32

33 Word Count/Limit: 2454/2500

34 Page count: 19

35 Figures: 3

36 References: 28

37

38 **ABSTRACT (250 words)**

39 **Objectives**

40 Tuberculosis (TB) is a common infection in HIV patients. Our study aims to determine
41 the prevalence and characteristics of HIV-TB co-infected patients in Singapore, a
42 high-income, intermediate TB-burden country.

43 **Methods**

44 Retrospective data of 11-years was obtained from the National University Hospital
45 (NUH), a quaternary care hospital and the National Centre for Infectious Diseases,
46 the national HIV centre.

47 **Results**

48 From December 2005 to December 2016, 48 out of 819 HIV patients and 272 out of
49 3,196 HIV patients who were managed in NUH and TTSH respectively, were
50 diagnosed with TB. 89.1% (n=285) were males and 2 (0.6%) were screened for
51 latent TB on HIV diagnosis. The median age at TB diagnosis was 47.3 years old
52 (Interquartile range, IQR 41-57). Mean CD4 count at TB diagnosis was 125.0 ± 153.9
53 cells/mm³. 124 (38.6%) patients had CD4 < 50 cells/mm³. 41.3% (n=132) of patients
54 had HIV diagnosed at least 6 weeks before TB diagnosis, indicating an opportunity to
55 initiate latent TB preventive therapy. 55.0% (n=176) had HIV and TB concomitantly
56 diagnosed within 6 weeks whilst 2.25% (n=7) had TB diagnosed before HIV. Of those
57 HIV-TB co-infected patients with CD4 < 50 cells/mm³, 18 (14.2%) had anti-retroviral
58 therapy (ART) started ≤ 2 weeks. TB-related mortality was 5.3% (n=17) and 3.75%
59 (n=12) were lost to follow-up.

60 **Conclusion**

61 There is a lack of latent TB screening in HIV patients and a delay in initiation of ART
62 in HIV-TB patients with low CD4 counts in our study. Clinical practices can be further
63 improved for the benefit of outcomes in HIV-TB patients.

64

65

66 **Introduction**

67 In 2019, there was an estimated 10 million new cases of tuberculosis (TB) diagnosed
68 globally, of whom 815,000 of them were among people living with HIV (1). People
69 living with HIV are more susceptible to active TB infection either from reactivation of
70 latent infection or primary infection. HIV infection is estimated to increase the risks of
71 developing TB by 16-27 times compared to those without HIV infection (2). TB
72 remains the leading cause of death in the HIV population worldwide even though TB
73 is both preventable and treatable. Globally, approximately 208,000 people with HIV
74 died from TB in 2019, which may be worsened by the COVID-19 pandemic (1).
75 Reasons for poorer clinical outcomes for HIV-TB co-infected patients include delays
76 in initiation of anti-retroviral therapy (ART) and/or TB treatment, late detection of HIV-
77 associated TB and multi-drug resistance TB (1).

78

79 World Health Organization (WHO) promotes preventive action through early
80 systematic screening and treatment for active and latent TB at the time of HIV
81 diagnosis (1). Treatment of latent TB infection (LTBI) is critical to reduce the risk of
82 progression to active TB with an efficacy ranging 60-90% (3). The guidelines
83 currently recommend testing LTBI using either Interferon Gamma Release Assay
84 (IGRA) or Tuberculin skin test (TST) in high-income and upper middle-income
85 countries with estimated TB incidence less than 100 per 100 000 as they are most
86 likely to benefit due to resource availability and TB epidemiology (3). Despite the end
87 TB strategy by WHO that aims to reduce the incidence rate of TB by 90% by 2035
88 (4), many countries are still not adhering to current guidelines. According to WHO,
89 the percentage of newly diagnosed HIV patients who received preventive LTBI
90 treatment in 2017 in Singapore, Indonesia, India, Philippines, Vietnam, Myanmar,
91 Cambodia was <1%, 16%, 10%, 57%, 31%, 17% and 21% respectively (5).

92

93 Singapore is a high-income economy country with an intermediate TB burden (6),
94 and a healthcare system that is consistently ranked as accessible, equitable and
95 cost-effective by international surveys (7)(8). In Singapore, HIV is managed mainly
96 by the National Centre for Infectious Disease (NCID) and is the national HIV referral
97 center. The HIV programme at the National University Hospital (NUH), a quaternary
98 care centre, was established in 2010. In 2018, out of the 1,421 TB cases who had a
99 HIV test performed, 28 cases (2.0%) were found to have HIV-TB co-infection (9).
100 This study was performed to determine the number of active TB cases in HIV
101 patients, and determine the clinical characteristics of this cohort of patients.

102

103 **Methods**

104 *Study population*

105 Clinical data were retrospectively obtained from TTSH (2005 - 2016) and NUH (2010
106 - 2016). We included all HIV-positive patients, confirmed by Western blot, of at least
107 age 18, who were treated for TB in both hospitals between December 2005 and
108 December 2016. Data collected were patient demographics including gender, age,
109 comorbidities, HIV diagnosis (date of diagnosis, date of initiation of ART, CD4 count
110 at HIV and TB diagnosis, HIV viral load at HIV and TB diagnosis, screening for LTBI
111 at HIV diagnosis), TB characteristics (date of diagnosis, symptoms and duration of
112 presentation, site of infection, method of diagnosis, presence of cavitation, chest
113 radiograph (CXR) findings, physical examination findings), treatment of TB (TB
114 regime and administration, development of IRIS) and clinical outcome (mortality, lost
115 to follow up, TB recurrence, cause of death).

116

117 *Definitions*

118 TB was microbiologically diagnosed by positive *Mycobacterium tuberculosis* cultures
119 or nucleic acid tests. Patients were considered to have clinical TB if they were on TB
120 treatment despite having negative cultures or nucleic acid test. Acid Fast Bacilli

121 (AFB) smear was graded from 0-4, HIV diagnosis was confirmed by Western blotting.
122 CXR were scored 0-10 based on the number of segments involved as previously
123 described by Lawson et al (10). For patients who received treatment in NUH, CXR
124 was scored independently by 3 clinical researchers (Teng V.Y.M, Chua Y.T, Ong
125 C.W.M), and a final score was obtained by the average of 3 scores. For patients
126 managed in TTSH, CXR was scored by a senior clinical researcher (Young, B). LTBI
127 was diagnosed using an interferon gamma release assay (IGRA) (Quantiferon-TB
128 Gold plus; Qiagen) or T-spot TB test (Oxford Immunotec) and/or tuberculin skin test
129 using purified protein derivative (PPD) solution with a cut-off of 10mm as per local
130 practice (9). Multidrug resistant TB was defined as *M.tuberculosis* resistant to both
131 isoniazid and rifampicin. Patients were considered lost to follow-up if they did not turn
132 up for follow up visits after starting treatment or if they have left the country without
133 completion of treatment.

134

135 *Data Analysis*

136 SPSS software (IBM SPSS, Version 24, USA) and Graphpad Prism (Version 7.0)
137 was used to perform descriptive statistical analyses. Correlation analysis was
138 performed using Spearman's coefficients and a $p < 0.05$ was considered statistically
139 significant.

140

141 *Ethics*

142 Ethics approval was granted by NHG Domain Specific Review Board (reference
143 number 2015/00945).

144

145 **Results**

146 During the 11-year study period, 4,015 HIV patients received medical treatment at
147 TTSH and NUH hospital. 48 out of 819 HIV patients and 272 out of 3,196 HIV
148 patients were diagnosed with TB, in NUH and TTSH respectively. Out of 320 eligible

149 patients, the majority were male, with a median age of 47.3 years (IQR 41-57) at TB
150 diagnosis. 93.8% of this cohort of patients were microbiologically-proven TB.
151 Smokers comprised 45% of the cohort and a small proportion had diabetes-mellitus
152 (12.5%) (Table 1).

153

154 The mean CD4 count at TB diagnosis was 125 ± 153.9 cells/mm³ (mean \pm S.D.) with
155 76% of patients having a CD4 count ≤ 200 cells/mm³ at the point of TB diagnosis,
156 indicating profound immunosuppression. Only 2 (0.6%) patients were screened for
157 LTBI upon HIV diagnosis, with equal proportion of unscreened patients above and
158 below CD4 count of 200 cells/mm³ (Table 1). Both patients were negative for LTBI by
159 IGRA or TST.

160

161 The most common clinical presentation for TB were fever (75.9%), cough (62%) and
162 weight loss (53.4%). 143 (44.7%) patients had only pulmonary involvement; 39
163 (12.2%) patients had extrapulmonary TB only and 135 (42.2%) patients had both
164 pulmonary and extrapulmonary TB. In total, 278 (86.9%) eligible patients had
165 pulmonary TB out of 320 patients. The lung was the most common site of TB
166 involvement independent of CD4 count. The most common site of extrapulmonary TB
167 was lymph node involvement for both cohorts above and below CD4 of 200
168 cells/mm³. In patients with CD4 ≤ 200 cells/mm³, 87% (n=213) had pulmonary TB
169 whilst 59% (n=144) had extra-pulmonary TB (Figure 1A). However, in those with CD4
170 > 200 cells/mm³, majority comprising 84% (n=53) had lung involvement whilst 39.6%
171 (n=25) had extra-pulmonary TB involvement (Figure 1B).

172

173 Of those with pulmonary TB, the median CXR score was 4. We found that a total of
174 84 (30.2%) patients had clear CXR despite the presence of pulmonary TB, most of
175 whom were patients with lower CD4 counts. For patients with CD4 ≤ 200 cells/mm³

176 with lung involvement, CXR can be normal which was seen in 37.9% (Figure 2A),
177 and the same is observed in the relative immunocompetent group (Figure 2B). Most
178 of patients in the $CD4 \leq 200$ cells/mm³ had positive AFB smear results (Figure 2C)
179 with 10% (n=21) of patients with diffuse lung involvement, having a CXR score of 10
180 (Figure 2A). However, in patients with $CD4 > 200$ cells/mm³ with lung involvement,
181 only 17% (n=9) patients had clear CXR with a range of AFB smears (Figure 2D),
182 whereas only 3.7% (n=2) patients had diffuse lung involvement (Figure 2B). In both
183 groups, a wide range of AFB smear score from 0 to 4 can be present in patients with
184 a normal CXR (Figure 2E and 2F), indicating that immunocompromised patients can
185 remain highly infectious despite having a normal CXR. Similarly, it was possible to
186 have an AFB smear score of 0 with diffuse TB lung involvement. Interestingly, the
187 AFB smear was positively associated with the degree of CXR score in patients with
188 $CD4 > 200$ cells/mm³ ($r = 0.33$, $p < 0.05$) but this association was not found in patients
189 whose $CD4 \leq 200$ cells/mm³ (Figure 2E and 2F).

190

191 41.3% (n=132) of patients had HIV diagnosed at least 6 weeks prior to TB diagnosis
192 with a median time-frame of 46 months (IQR 12-91 months) (Figure 3). The mean
193 duration of active TB treatment was 8.2 ± 3.5 months. The majority of patients (83%)
194 were on directly observed treatment (DOT). A small proportion of patients had TB
195 recurrence (3.8%) and development of immune reconstitution inflammatory
196 syndrome (IRIS) (15.6%). Lost to follow-up rate (3.75%) was low, including those
197 who left the country or defaulted follow-up. All cause-mortality was 10% (n=32), out
198 of whom 53% consist of TB-related mortality (n=17) (Table 1).

199

200 **Discussion**

201 In our study, there was a significant proportion of patients (41%) who had HIV
202 diagnosed at least 6 weeks before TB diagnosis. As culture is the gold standard for

203 diagnosis of active TB and culture result takes 2 to 6 weeks to process, our study
204 team considered 6 weeks to be a reasonable time frame to exclude concurrent HIV-
205 TB on presentation (11). Our cohort mainly consisted of clinically advanced HIV
206 disease as 76% had $CD4 \leq 200$ cells/mm³ at TB diagnosis. However, only 0.6%
207 (n=2) of patients in this study had LTBI screened upon HIV diagnosis, which is a
208 considerably low given WHO recommendations. In developed countries with low TB
209 and HIV burden, the compliance of HIV services in implementing LTBI screening was
210 often inadequate; the LTBI screening rates among HIV patients in United Kingdom,
211 United States and New Zealand was 35%, 32% and 55% respectively (12)(13)(14).
212 The local medical community can further improve on this aspect to prevent active TB
213 in the HIV population.

214

215 Our study found higher rates of TB-HIV co-infection in males. This is in keeping with
216 a systematic review done in the European Union which reported that the majority of
217 HIV-TB co-infected cases were male and young adults, aged between 25-45 years
218 (15). We also found that the prevalence of diabetes mellitus (DM) in our cohort was
219 12% which was similar to a study conducted by Bizune et al in the United States,
220 which reported a prevalence of 9% (16). The high proportion can be explained by
221 diabetes predisposing to TB and ART increasing the risk of metabolic syndrome and
222 thus predisposing to DM (17), and also underscores the increase in DM prevalence
223 in developed countries.

224

225 Other significant findings in our study included lower than expected proportion (23%)
226 of patients who were already on ART when diagnosed with TB. This is in contrast
227 with studies in India and Africa which found that 58% and 40% of HIV-infected patient
228 were already receiving ART respectively (18)(19). This difference can be explained
229 by a significant proportion (55%) of our cohort with TB and HIV diagnosed

230 concomitantly within 6 weeks, hence many of them were not expected to be on ART
231 when diagnosed with TB.

232

233 Existing studies have reported a variety of chest radiographic appearances of active
234 TB in HIV-positive patients, depending on their level of immunity. In
235 immunocompromised patients, clinical manifestations are atypical as AFB smear can
236 often be positive with normal CXR, or infiltrates are more often present in the lower
237 than the upper lobes (20). 33.5% of our cohort with pulmonary TB had normal CXR
238 which is slightly higher than that reported in other studies which range from 6-21%
239 (21) and may be due to our cohort being more immunocompromised with a mean
240 CD4 count of 125 cells/mm³. Therefore, clinicians should exercise caution when
241 using CXR to screen for active TB disease in HIV patients. A high index of suspicion
242 especially in patients presenting with prolonged cough, is required for timely
243 diagnosis of TB in HIV positive patients.

244

245 We found 90% of our HIV-TB cohort to be AFB smear positive with 89% in the group
246 with CD4 ≤ 200 cells/mm³ and 94% in the CD4 > 200 cells/mm³. This is in contrast to
247 previous studies which reported lower prevalence rates (50-70%) with positive AFB
248 sputum smears in HIV patients (21). This difference may be contributed by higher
249 sensitivity used in our laboratory and other studies not reporting trace results from
250 smear tests, leading to lower rates of smear negative results. The mycobacterial
251 burden was also significantly associated with the degree of CXR involvement only in
252 those with CD4 > 200 cells/mm³.

253

254 WHO recommends initiation of ART for HIV-TB coinfecting patients within the first 2
255 months of starting TB treatment and within 2 weeks in those severely
256 immunocompromised patients with CD4 counts <50 cells/mm³. Prompt initiation of
257 ART to HIV-TB co-infected patients reduces mortality especially in advanced HIV

258 disease (22). Our study showed that only 14% of patients with $CD4 \leq 50$ cells/mm³
259 had ARV initiated within 2 weeks. In addition, there was a significant proportion
260 (51.7%) of patients who initiated ART more than 2 months of TB diagnosis, out of
261 which 89% were from patients managed prior to 2011. Majority of delay in ART
262 initiation were prior to the revised WHO ART initiation guidelines in 2010 (23). A
263 study by Escada et al in Brazil found that only 5.4% of patients were initiated on ART
264 within 2 weeks of starting TB treatment, however their cohort had a higher median
265 CD4 count of 91 cells/mm³ (24).

266

267 DOT is recommended by WHO to promote TB treatment adherence as suboptimal
268 adherence has been associated with unfavourable clinical outcomes (25). Our cohort
269 was able to achieve 83% on DOT, with the remaining using self-administered
270 treatment (SAT). There was a wide variability in the success of implementing DOT in
271 other countries, ranging from 24% in South Africa (26) to 91% in Philippines in HIV-
272 TB co-infected patients (27). The main challenges faced worldwide included poor
273 public health infrastructure, poor social support, inadequate funding and lack of
274 awareness about the strategy among practitioners especially in low income,
275 developing countries (27). In our study, TB-related mortality rate was 5.3%. This is
276 much lower than the global rate in 2008 in which TB accounted for about 26% of HIV-
277 related deaths (28). Overall, there is ample room for improvement to comply with
278 international guidelines to reduce mortality in our HIV population.

279

280 The main strength of this study is the detailed clinical data collected for analysis over
281 a 5-year period of cohort of 320 patients. Study limitations include missing data given
282 that this was a retrospective study. In addition, although one of our centres is a
283 referral centre for HIV in Singapore, our data may not be representative of the
284 national HIV-TB situation of the country.

285

286 **Conclusion**

287 Early diagnosis of LTBI enables prompt effective treatment to prevent TB-associated
288 deaths. Further improvements are needed to offer routine LTBI screening and
289 treatment in all HIV patients, as recommended by the WHO. In our high-income
290 intermediate TB burden country, there remains a good window of opportunity to
291 reduce the prevalence of HIV-TB co-infection, together with prompt initiation of ART
292 to improve treatment outcomes in this population.

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314 **Acknowledgements**

315 Catherine W. M. Ong is funded by Singapore National Medical Research Council
316 (NMRC/TA/0042/2015, CSAINV17nov014); National University Health System
317 Singapore (NUHS/RO/2017/092/SU/01, CFGFY18P11,
318 NUHSRO/2020/042/RO5+5/ad-hoc/1), iHealthtech in NUS and recipient of the Young
319 Investigator Award, Institut Merieux, Lyon, France.

320

321 **Author contributions**

322 Ong C.W.M, Archuleta S. conceived the study. Teng V.Y.M., Chua Y.T., Lai E.E.N.,
323 Mukherjee S., Michaels J. and Young B. obtained the data. Teng V.Y.M., Chua Y.T.,
324 Lai E.E.N. analysed the data. Teng V.W.M, and Ong C.W.M co-wrote the first draft.
325 All authors edited and approved the final version of the manuscript.

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342 References

- 343 1. World Health Organization. Global Tuberculosis Report 2020 [Internet]. WHO.
344 World Health Organization; [cited 2021 Jan 17]. Available from:
345 [https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-](https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf)
346 [eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf)
- 347 2. WHO | Tuberculosis and HIV [Internet]. WHO. World Health Organization; [cited
348 2020 Jul 25]. Available from: http://www.who.int/hiv/topics/tb/about_tb/en/
- 349 3. WHO | WHO guidelines on the management of latent tuberculosis infection
350 launched today [Internet]. WHO. World Health Organization; [cited 2020 Nov
351 29]. Available from: https://www.who.int/tb/features_archive/LTBI/en/
- 352 4. WHO | The End TB Strategy [Internet]. WHO. World Health Organization; [cited
353 2020 Nov 29]. Available from: <http://www.who.int/tb/strategy/end-tb/en/>
- 354 5. Paton NI, Borand L, Benedicto J, Kyi MM, Mahmud AM, Norazmi MN, et al.
355 Diagnosis and management of latent tuberculosis infection in Asia: Review of
356 current status and challenges. *International Journal of Infectious Diseases*.
357 2019 Oct 1;87:21–9.
- 358 6. Tam G, Lai SW. Is Singapore on track to eliminate tuberculosis by 2030? A policy
359 case study. *SAGE Open Med* [Internet]. 2019 May 19 [cited 2020 Jul 25];7.
360 Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537069/>
- 361 7. Bloomberg's Global Health Index For 2020 | Worldhealth.net Anti-Aging News
362 [Internet]. [cited 2020 Nov 29]. Available from:
363 <https://worldhealth.net/news/bloombergs-global-health-index-2020/>
- 364 8. Tandon A, Murray CJ, Lauer JA, Evans DB. Measuring Overall Health System
365 Performance for 191 Countries. :23.
- 366 9. Communicable Diseases Surveillance Singapore 2018. [Internet]. Communicable
367 Diseases Division, Ministry of Health, Singapore; [cited 2020 Nov 29]. Available
368 from: [https://www.moh.gov.sg/docs/librariesprovider5/diseases-](https://www.moh.gov.sg/docs/librariesprovider5/diseases-updates/communicable-diseases-surveillance-in-singapore-2018210c9a3beaa94db49299c2da53322dce.pdf)
369 [updates/communicable-diseases-surveillance-in-singapore-](https://www.moh.gov.sg/docs/librariesprovider5/diseases-updates/communicable-diseases-surveillance-in-singapore-2018210c9a3beaa94db49299c2da53322dce.pdf)
370 [2018210c9a3beaa94db49299c2da53322dce.pdf](https://www.moh.gov.sg/docs/librariesprovider5/diseases-updates/communicable-diseases-surveillance-in-singapore-2018210c9a3beaa94db49299c2da53322dce.pdf)
- 371 10. Lawson L, Yassin MA, Thacher TD, Olatunji OO, Lawson JO, Akingbogun TI, et
372 al. Clinical presentation of adults with pulmonary tuberculosis with and without
373 HIV infection in Nigeria. *Scandinavian Journal of Infectious Diseases*. 2008
374 Jan;40(1):30–5.
- 375 11. Kwan CK, Ernst JD. HIV and Tuberculosis: a Deadly Human Syndemic. *Clinical*
376 *Microbiology Reviews*. 2011 Apr 1;24(2):351–76.
- 377 12. Latent tuberculosis infection screening and treatment in HIV: insights from
378 evaluation of UK practice | *Thorax* [Internet]. [cited 2020 Dec 1]. Available from:
379 <https://thorax.bmj.com/content/72/2/180>
- 380 13. Adams JW, Howe CJ, Andrews AC, Allen SL, Vinnard C. Tuberculosis screening
381 among HIV-infected patients: tuberculin skin test vs. interferon-gamma release
382 assay. *AIDS Care*. 2017 Dec;29(12):1504–9.

- 383 14. Anwara O, Patrick M, Edeogu C, Kelechi O, Moses A, Oka G. The prevalence of
384 diabetes mellitus in human immunodeficiency virus seropositive subject's co-
385 infected with mycobacterium tuberculosis. :8.
- 386 15. Pimpin L, Drumright LN, Kruijshaar ME, Abubakar I, Rice B, Delpech V, et al.
387 Tuberculosis and HIV co-infection in European Union and European Economic
388 Area countries. *European Respiratory Journal*. 2011 Dec 1;38(6):1382–92.
- 389 16. Bizune DJ, Kempker RR, Kagei M, Yamin A, Mohamed O, Holland DP, et al.
390 Treatment Complexities Among Patients with Tuberculosis in a High HIV
391 Prevalence Cohort in the United States. *AIDS Res Hum Retroviruses*. 2018 Dec
392 1;34(12):1050–7.
- 393 17. Brown TT, Tassiopoulos K, Bosch RJ, Shikuma C, McComsey GA. Association
394 between systemic inflammation and incident diabetes in HIV-infected patients
395 after initiation of antiretroviral therapy. *Diabetes Care*. 2010 Oct;33(10):2244–9.
- 396 18. Kumar AMV, Singarajipura A, Naik B, Guddemane DK, Patel Y, Shastri S, et al.
397 HIV-infected presumptive tuberculosis patients without tuberculosis: How many
398 are eligible for antiretroviral therapy in Karnataka, India? *Journal of*
399 *Epidemiology and Global Health*. 2017 Mar 1;7(1):11–9.
- 400 19. Pathmanathan I, Pasipamire M, Pals S, Dokubo EK, Preko P, Ao T, et al. High
401 uptake of antiretroviral therapy among HIV-positive TB patients receiving co-
402 located services in Swaziland. *PLOS ONE*. 2018 May 16;13(5):e0196831.
- 403 21. Lee MP, Chan JWM, Ng KKP, Li PCK. Clinical manifestations of tuberculosis in
404 HIV-infected patients. *Respirology*. 2000 Dec;5(4):423–6.
- 405 22. WHO | Universal antiretroviral therapy (ART) for all HIV-infected TB patients
406 [Internet]. WHO. World Health Organization; [cited 2020 Jul 8]. Available from:
407 https://www.who.int/hiv/topics/tb/art_hivpatients/en/
- 408 23. WHO | Antiretroviral therapy for HIV infection in adults and adolescents [Internet].
409 WHO. World Health Organization; [cited 2021 Feb 7]. Available from:
410 <https://www.who.int/hiv/pub/arv/adult2010/en/>
- 411 24. da Silva Escada RO, Velasque L, Ribeiro SR, Cardoso SW, Marins LMS,
412 Grinsztejn E, et al. Mortality in patients with HIV-1 and tuberculosis co-infection
413 in Rio de Janeiro, Brazil - associated factors and causes of death. *BMC Infect*
414 *Dis*. 2017 May 30;17(1):373.
- 415 25. A patient-level pooled analysis of treatment-shortening regimens for drug-
416 susceptible pulmonary tuberculosis | *Nature Medicine* [Internet]. [cited 2021 Jan
417 17]. Available from: <https://www.nature.com/articles/s41591-018-0224-2>
- 418 26. Howell EM, Kigozi NG, Heunis JC. Community-based directly observed treatment
419 for TB patients to improve HIV services: a cross-sectional study in a South
420 African province. *BMC Health Serv Res* [Internet]. 2018 Apr 7 [cited 2020 Dec
421 2];18. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889613/>
- 422 27. Cai E, Chua S, Tan M, Tambyah P. Tuberculosis care: enhancing directly
423 observed therapy in a peri-urban, low socioeconomic status neighbourhood.
424 *smedj*. 2019 Jul;60(7):334–6.


425 28. Getahun H, Gunneberg C, Granich R, Nunn P. HIV Infection—Associated
426 Tuberculosis: The Epidemiology and the Response. *Clinical Infectious*
427 *Diseases*. 2010 May 15;50(Supplement_3):S201–7.

428


1 **Table 1: Baseline characteristics of HIV-TB co-infected patients**

Characteristics	N=320
Gender, n (%)	
Male	285 (89.1)
Female	33 (10.3)
Transgender	2 (0.6)
Age at HIV diagnosis, median (IQR)	43.4 (37-55)
Age at TB diagnosis, median (IQR)	47.3 (41-57)
TB diagnosed by, n (%)	
Nucleic acid tests (eg. GeneXpert)	133 (41.4)
TB cultures	272 (84.7)
Clinical diagnosis	20 (6.2)
Previous TB history, n (%)	26 (8.1)
Presence of TB contact history, n (%)	27 (8.4)
Smoker, n (%)	144 (44.9)
Alcoholism, n (%)	76 (23.7)
History of cancer, n (%)	10 (3.1)
Diabetes mellitus, n (%)	40 (12.5)
End Stage Kidney Disease, n (%)	1 (0.3)
Hepatitis B, n (%)	31 (9.7)
Hepatitis C, n (%)	13 (4.0)
Receiving ART when diagnosed with TB, n (%)	74 (23.1)
Screened for latent TB upon HIV diagnosis, n (%) ¶	2 (0.6)
CD4 at TB diagnosis, mean ± s.d.	125.0 ± 153.9cells/mm ³
CD4 >200cell/mL, n (%)	63 (19.6)
CD4 50-200 cells/mL, n (%)	120 (37.4)
CD4 <50 cells/mL, n (%)	124 (38.6)
Unknown, n (%)	13 (4.1)
HIV viral load at TB diagnosis, mean ± s.d.	935,142 ± 5,361,346 copies/ml
Direct Observed Treatment, n (%)	267 (83)
Multi-drug resistant TB, n (%)	6 (1.9)
Time of starting ART, n (%)	
CD4≤50 cells/mm ³	127 (39.7)
<2 weeks	18 (14.2)
2-8 weeks	27 (21.3)
>8 weeks	57 (44.9)
CD4>50 cells/mm ³	179 (55.9)
<2 weeks	22 (12.3)
2-8 weeks	44 (24.6)
>8 weeks	62 (34.6)
Recurrence of TB, n (%)	12 (3.75)
Development of paradoxical IRIS, n (%)	50 (15.6)
Duration of TB treatment, mean ± s.d.	8.2 ± 3.5 months
Died, n (%)	32 (10)
TB-related	17 (5.3)
Non TB related	15 (4.7)
Lost to follow up, n (%)	12 (3.75)
Time between HIV diagnosis and death, median (IQR)	530 days (274-2413)

- 2 ART, Anti-retroviral therapy; HIV, Human immuno-deficiency virus; IQR, Inter-quartile
3 range; IRIS, Immune reconstitution inflammatory syndrome; SD, standard deviation,
4 TB, Tuberculosis.
5 ¶: Latent TB defined by positive testing by TST (tuberculin skin test) or IGRA
6 (interferon gamma release assay)




1



2

3 **Figure 1: Sites of TB infection in HIV-TB patients.** (A) Patients with $CD4 \leq 200$
4 $cells/mm^3$ at TB diagnosis. (B) Patients with $CD4 > 200$ $cells/mm^3$ at TB diagnosis

1



2

3 **Figure 2: Characteristics of pulmonary TB in HIV patients.**

4 (A) Chest radiograph score of patients with CD4 ≤ 200 cells/mm³ at TB diagnosis. (B)

5 Chest radiograph score of patients with CD4 > 200 cells/mm³ at TB diagnosis. (C)

6 AFB smear quantity in patients with pulmonary TB, with CD4 ≤ 200 cells/mm³ at TB


7 diagnosis. (D) AFB smear quantity in patients with pulmonary TB, with CD4 > 200

8 cells/mm³ at TB diagnosis. (E) Association of AFB smear with chest radiograph in

9 patients with CD4 ≤ 200 cells/mm³ at TB diagnosis. (F) Association of AFB smear with

10 chest radiograph in patients with CD4 > 200 cells/mm³ at TB diagnosis.

1



2
3

3: Time to TB diagnosis relative to HIV diagnosis

